Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Lags Revenue Estimates
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.37 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $0.44 per share a year ago.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?
CRISPR Therapeutics heads into Q4 earnings with rising Casgevy sales, collaboration revenues from Vertex, and a history of beating estimates.
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $51.31, denoting a +2.7% move from the preceding trading day.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $54.65, marking a -1.57% move from the previous day.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $55.52, moving 8.7% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors
CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $54.21, signifying a -4.71% move from its prior day's close.
Crispr Therapeutics: Patience And Opportunity Through Volatility
Crispr Therapeutics remains highly volatile, disconnected from near-term fundamentals, yet I see long-term value far above current levels. CRSP's business progress is slow, with pipeline milestones and cash runway—not quarterly EPS—being the most relevant metrics for investors. Key risks include the commercial ramp of Casgevy, pipeline execution, and surviving cash burn until anticipated profitability in 2028.
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Therapeutics AG (CRSP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CRISPR Therapeutics AG (CRSP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
